Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Recent Advances and Strategies

Overview

Journal JCO Oncol Pract

Specialty Oncology

Date 2024 Mar 12

PMID 38471052

Authors

Francisco J Esteva

Elena Katz

Affiliations

Soon will be listed here.

Abstract

Neoadjuvant HER2 Therapy: Beyond one-size-fits-all.

Citing Articles

Comprehensive review of drug resistance in mammalian cancer stem cells: implications for cancer therapy.

Mengistu B, Tsegaw T, Demessie Y, Getnet K, Bitew A, Kinde M Cancer Cell Int. 2024; 24(1):406.

PMID: 39695669 PMC: 11657890. DOI: 10.1186/s12935-024-03558-0.

Use of Antibody-Drug Conjugates in the Early Setting of Breast Cancer.

Koukoutzeli C, Trapani D, Ascione L, Kotteas E, Marra A, Criscitiello C Clin Med Insights Oncol. 2024; 18:11795549241260418.

PMID: 38894701 PMC: 11185006. DOI: 10.1177/11795549241260418.

References

Baselga J, Gelmon K, Verma S, Wardley A, Conte P, Miles D . Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010; 28(7):1138-44. PMC: 4979216. DOI: 10.1200/JCO.2009.24.2024. View

Pegram M, Pienkowski T, Northfelt D, Eiermann W, Patel R, Fumoleau P . Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst. 2004; 96(10):759-69. DOI: 10.1093/jnci/djh133. View

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

Boulbes D, Arold S, Chauhan G, Blachno K, Deng N, Chang W . HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Mol Oncol. 2014; 9(3):586-600. PMC: 4815926. DOI: 10.1016/j.molonc.2014.10.011. View

Tolaney S, Tarantino P, Graham N, Tayob N, Pare L, Villacampa G . Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 2023; 24(3):273-285. DOI: 10.1016/S1470-2045(23)00051-7. View

Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R . Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013; 24(9):2278-84. DOI: 10.1093/annonc/mdt182. View

Sparano J, Zhao F, Martino S, Ligibel J, Perez E, Saphner T . Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. J Clin Oncol. 2015; 33(21):2353-60. PMC: 4500829. DOI: 10.1200/JCO.2015.60.9271. View

Tan A, Im S, Mattar A, Colomer R, Stroyakovskii D, Nowecki Z . Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2020; 22(1):85-97. DOI: 10.1016/S1470-2045(20)30536-2. View

Esteva F, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G . Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial. Cancer Chemother Pharmacol. 2019; 84(4):839-847. PMC: 6768896. DOI: 10.1007/s00280-019-03920-4. View

10.

Harbeck N, Gluz O, Christgen M, Kates R, Braun M, Kuemmel S . De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and.... J Clin Oncol. 2017; 35(26):3046-3054. DOI: 10.1200/JCO.2016.71.9815. View

11.

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M . Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365(14):1273-83. PMC: 3268553. DOI: 10.1056/NEJMoa0910383. View

12.

Fu C, Stebbing J, Esteva F . Clinical development of CT-P6 in HER2 positive breast cancer. Expert Opin Biol Ther. 2019; 19(10):987-992. DOI: 10.1080/14712598.2019.1665019. View

13.

Emens L, Esteva F, Beresford M, Saura C, De Laurentiis M, Kim S . Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020; 21(10):1283-1295. DOI: 10.1016/S1470-2045(20)30465-4. View

14.

Broglio K, Quintana M, Foster M, Olinger M, McGlothlin A, Berry S . Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. JAMA Oncol. 2016; 2(6):751-60. DOI: 10.1001/jamaoncol.2015.6113. View

15.

Perez-Garcia J, Gebhart G, Borrego M, Stradella A, Bermejo B, Schmid P . Chemotherapy de-escalation using an F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol. 2021; 22(6):858-871. DOI: 10.1016/S1470-2045(21)00122-4. View

16.

Buzdar A, Ibrahim N, Francis D, Booser D, Thomas E, Theriault R . Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23(16):3676-85. DOI: 10.1200/JCO.2005.07.032. View

17.

Nahta R, Esteva F . Trastuzumab: triumphs and tribulations. Oncogene. 2007; 26(25):3637-43. DOI: 10.1038/sj.onc.1210379. View

18.

Gluz O, Nitz U, Christgen M, Kuemmel S, Holtschmidt J, Schumacher J . Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial. JAMA Oncol. 2023; 9(7):946-954. PMC: 10176180. DOI: 10.1001/jamaoncol.2023.0646. View

19.

Hurvitz S, Martin M, Jung K, Huang C, Harbeck N, Valero V . Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. J Clin Oncol. 2019; 37(25):2206-2216. PMC: 6774816. DOI: 10.1200/JCO.19.00882. View

20.

Valero V, Forbes J, Pegram M, Pienkowski T, Eiermann W, von Minckwitz G . Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active.... J Clin Oncol. 2010; 29(2):149-56. DOI: 10.1200/JCO.2010.28.6450. View